Beta Bionics wins FDA clearance for Mint patch pump and files next AI dosing algorithm

Beta Bionics, Inc. (Nasdaq: BBNX) said the U.S. Food and Drug Administration cleared Mint, its new patch insulin pump that needs no recharging, works with major continuous glucose monitors (CGMs), and can be controlled from iOS and Android phones — and the same company release unveils 3D Intelligence, its next insulin dosing algorithm, already submitted to the FDA through a 510(k) application, with full U.S. Mint commercialization aimed for Q1 2027 while algorithm-powered Mint 3D and iLet 3D launches remain subject to separate FDA clearance.

Medical AI is not only chatbots in clinics — it is also the dosing brain inside insulin pumps. A public diabetes company just cleared new patch-pump hardware at FDA and put its next adaptive dosing algorithm into review, which is a concrete HEALTH signal about how AI reaches patients who need insulin every day.

Beta Bionics, Inc., an Irvine, California diabetes-device company listed as Nasdaq: BBNX, said via GlobeNewswire that the U.S. Food and Drug Administration cleared Mint, its new patch insulin pump. A patch pump is a small insulin pump worn on the skin instead of a pump on a belt with a long tube. The company describes Mint as a reusable-plus-disposable design that does not need recharging, works with major continuous glucose monitors, and can be controlled from iOS and Android phones. That company release, dated 14 Sep 2026 at 07:30 ET, is the filing event. This desk did not review the FDA clearance letter.

A continuous glucose monitor, or CGM, is a sensor worn on the body that reads sugar levels through the day so a person does not have to prick a finger for every check. Automated insulin delivery, or AID, is the pairing of that sensor with a pump and software that adjusts insulin without the person calculating every dose. File Mint as cleared hardware. Do not upgrade that clearance to a cleared dosing brain.

In the same release the company unveils 3D Intelligence, which it calls its next insulin dosing algorithm — the software that decides how much insulin to give. Beta Bionics says it has submitted 3D Intelligence to the FDA through a 510(k) application. A 510(k) is the FDA’s common review path for a new device the maker says is substantially equivalent to something already cleared. A submission is a filing for review. It is not a clearance. 3D Intelligence is not FDA-cleared in this release.

The company says 3D Intelligence is designed with three algorithm experiences so a clinician can pick a style for each patient: Original — the algorithm already on iLet, which Beta Bionics says has real-world use across more than 40,000 users; Optimized — an enhanced version that the company says builds on that iLet experience; and Conservative — a more measured response when correcting high sugar. File the three names and the 40,000-user line as company claims. This desk did not audit user counts or outcomes.

Subject to separate FDA clearance, the company expects 3D Intelligence to power iLet 3D in the United States by the end of 2026, and Mint 3D at the full Mint launch. Do not treat either algorithm-powered launch as cleared or on sale today. The release marks those products investigational.

Sean Saint, President and CEO, said the next-generation AID platform of Mint 3D and iLet 3D “will represent a transformational advancement for people living with diabetes, subject to regulatory clearance by the FDA.” He said the design is meant to offer a choice between a patch pump and a tubed pump, plus an algorithm experience suited to each person, “with a particular focus on improving affordability through our efforts to expand access for both iLet and Mint in the pharmacy channel.” File the quote. “Subject to regulatory clearance” is his caveat. This is not an outcomes study from this desk.

The company expects to start full U.S. commercialization of Mint in the first quarter of 2027, and says that is ahead of its previous target. It also expects manufacturing capacity to produce at least 1.5 million disposable Mint units in 2027, and says it may be able to exceed that if it adds staff, automation, and yield. File the calendar and the 1.5 million figure as company expectations — not as units already built, and not as a sales forecast from this desk.

Mint is expected to launch only through the pharmacy channel, the company says, with about 40% of insured U.S. lives able to buy it on a pharmacy benefit at launch, and coverage expected to reach at least 50% of insured U.S. lives within the first year. File those shares as Beta Bionics’ market-access claims. This desk did not check insurer lists.

On the same release the company updated full-year 2026 revenue guidance to about $121 million to $126 million, from a previous $131 million to $136 million. It attributes a possible revenue deferral of up to $10 million in the fourth quarter of 2026 to new prospective iLet users who might wait for Mint. Those figures are company guidance only. They are not an audited close, not a stock call, and not investment advice from this desk.

CONFIRMED here: Beta Bionics’ 14 Sep 2026 GlobeNewswire release at 07:30 ET — PRIMARY company source. Hardware clearance is Mint the patch pump. 3D Intelligence is a 510(k) submission, not an FDA clearance. Revenue figures are company guidance only. NOT claimed: that the dosing algorithm is cleared, independent clinical outcomes, that this desk reviewed the FDA letter, or investment advice. Distinct from the already-filed tandem-health-100m-series-b — a European clinic-AI raise — intuitive-davinci-sp-ce-europe — a Europe surgical-robot CE mark — and i3lung-ai-nsclc-immunotherapy — a lung-cancer AI paper. This filing is the Mint hardware clearance plus the 3D Intelligence 510(k) submission only.